Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Adlai Nortye

<< Previous

Bullboard Posts

Next >>

Comment by inthnoon Sep 29, 2022 11:46am

186 Views

Post# 34995001

RE:RE:RE:RE:RE:Adlai Nortye

Nothing personal Noteable, but you have no idea as to whether or not the results have been embargoed. It is your opinion only and you should state such. Also you are suggesting that Merck pfizer is fliling for a BLA. Where did you get that information. A lot of your posts are very informative and appreciated but enough of your 2 cents and analysis as no one has been right to date about what is going on.

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects